Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
By: PR Newswire Association LLC. - 25 Apr 2024 | Back to overview list |
|
ROCKVILLE, Md., April 25, 2024 /PRNewswire/ -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31 to June 4, 2024. C-CAR031 is based on a novel GPC3-targeting CAR-T designed by AstraZeneca (LSE/STO/Nasdaq: AZN) using their transforming growth factor-beta receptor II (TGF?RII) dominant negative armoring discovery platform and is manufactured by AbelZeta in China. C-CAR031 is being developed in China under a co-development agreement between AbelZeta and AstraZeneca.1 Details of the oral presentation are as follows: Abstract Title: "Phase I study of C-CAR031, a GPC3-specific TGF?RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)." About AbelZeta Pharma, Inc. Forward-Looking Statements Company Contact: References 1. AbelZeta. AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China. December 2023. https://www.abelzeta.com/abelzeta-pharma-announces-agreement-with-astrazeneca-to-co-develop-a-novel-glypican-3-gpc3-armored-car-t-therapy-in-china/
View original content to download multimedia:https://www.prnewswire.com/news-releases/abelzeta-announces-abstract-for-c-car031-accepted-for-presentation-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting-302127271.html SOURCE AbelZeta Pharma, Inc. |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |